ABSTRACT
Abstract Background: Obesity is a public health problem and has been associated with the development of metabolic disorders that have a strong relationship with the onset of cardiovascular diseases (CVD). Objective: The objective was to analyze the influence of abdominal obesity (AO) on systemic arterial hypertension (SAH) and on the lipid profile in cardiovascular risk stratification in adult women. Methods: Altogether, 91 women participated in the research. Lifestyle information was collected, in addition to the analysis of clinical measures of cardiovascular risk and biochemical parameters. Unpaired Student's t-test, logistic regression, and Pearson's correlation were performed for data analysis, with a value of p <0.05 considered significant. Results: The prevalence of AO was 62.6%. Logistic regression showed that AO increased the chance of developing SAH by 2.9-fold. The same behavior was observed in the TG/HDL-c lipid ratio (3.93 ± 0.3 vs. 2.16 ± 0.2), representing an 82% increase in obese women. The present study also demonstrated that the best anthropometric parameter to analyze cardiovascular risk in the studied population was the waist/height ratio (AUC = 0.707). Conclusions: It can therefore be concluded that AO plays a significant role in the development of SAH and changes in lipid values that predict increased cardiovascular risk, configuring a strong influence factor for CVD.
ABSTRACT
A Hipertensão Arterial Sistêmica (HAS) é uma condição clínica multifatorial, com tratamento não-farmacológico e/ou farmacológico, que necessita de acompanhamento farmacoterapêutico para gestão da condição de saúde. O objetivo foi avaliar o impacto de um programa de acompanhamento farmacoterapêutico em pacientes com HAS, através do estudo quase-experimental, longitudinal e prospectivo. Foram avaliados 28 pacientes, 50% estavam com pressão arterial descompensada, os PRM (Problemas Relacionados à Medicamentos) identificados foram interações medicamentosas (57,1%), duplicidade farmacoterapêutica (28,8%), medicamentos potencialmente inapropriados para idosos (38,5 %) e não adesão ao tratamento (89,3%). Dos RNM (Resultado Negativos associados à Medicação) 56,2% relacionavam-se à segurança e 37,5% à efetividade. Após o acompanhamento, 56,3% dos RNM foram resolvidos, 57,1% dos pacientes aderiram ao tratamento e houve redução da Pressão Arterial Sistólica (p=0,010) e Pressão Arterial Diastólica (p=0,020). O programa mostrou-se favorável na redução da pressão arterial sistêmica e resolução dos PRM e RNM.
Systemic Arterial Hypertension (SAH) is a multifactorial clinical condition with non-pharmacological and/or pharmacological treatment that requires pharmacotherapeutic monitoring in order to manage the health condition. The objective was to evaluate the impact of a pharmacotherapeutic follow-up program of patients with SAH through a quasi-experimental, longitudinal, and prospective study. Twenty-eight patients were evaluated, 50% of which had decompensated blood pressure; the DRPs identified were drug interactions (57.1%), pharmacotherapeutic duplication (28.8%), potentially inappropriate medication use in older adults (38.5%), and non-adherence to treatment (89.3%). Of the NOM identified (Negative Outcomes associated with Medication), 56.2% were related to safety, and 37.5% to effectiveness. After the follow-up, 56.3% of the NOM were resolved, 57.1% of patients adhered to treatment, and there was a reduction in the Systolic Blood Pressure (p = 0.010) and Diastolic Blood Pressure (p = 0.020). The program proved to be efficient in reducing systemic blood pressure and resolving DRPs and NOM.